Clasp Therapeutics emerges with $150M based on work from Bert Vogelstein, Drew Pardoll

GO BACK TO PRESS RELEASES & MEDIA Endpoints News March 20, 2024 Clasp Therapeutics emerges with $150M based on work from Bert Vogelstein, Drew Pardoll Researchers at Johns Hopkins University have launched another biotech that builds on more than a decade of investigation that they hope will improve T cell engagers and limit their off-tumor toxicities. Bert Vogelstein, who founded companies like Thrive and Haystack Oncology, has been working with Drew Pardoll for years on mutation-associated neoantigens, or MANAs. They formed a biotech around the idea in 2020, naming it ManaT Bio.